Mealey's (March 18, 2020, 11:11 AM EDT) -- WASHINGTON, D.C. — Although reversing and remanding a New Jersey federal judge’s determination that various claims of one patent covering a type of treating type 2 diabetes mellitus is drawn to patent-ineligible subject matter, the Federal Circuit U.S. Court of Appeals on March 16 upheld a bench trial judgment that claims of two other patents in suit are invalid for obviousness and obviousness-type double patenting (Boehringer Ingelheim Pharmaceuticals Inc., et al. v. Mylan Pharmaceuticals Inc., et al., No. 19-1172, Fed. Cir., 2020 U.S. App. LEXIS 8393)....